Kornimate/medical-research-clean huggingface dataset:
visual guidelines and tutoring in pediatric urological surgery

Conditions: Hypospadias; Undescended Testis; Hydrocele; Ureteropelvic Junction Stenosis; Anxiety

Summary: the aim of this study is checking impact of visual guidelines (picture book) and tutoring in pediatric urologic surgery

the number of operations in pediatric urology performed on the basis of one day surgery has been increased tremendously over the last years. the shortening of the hospital admission intends to increase the efficacy of the health system, however at the same time puts an additional burdening regarding the postoperative care on the parents of the operated children. the parents often have no or has little experience with regards to the basic medical education. the lack of the proper tutoring in terms of possible complications, normal postoperative period may cause unnecessary patients and parents anxiety, visit to the emergency room or calls to the medical stuff, and in some case delay medical attention which can cause major surgery related complications. visual guidelines and tutoring of the patients upon surgery may avoid these undesirable effects of the early hospital discharge patients and methods: the investigators are proposing prospective study of 3 groups of patients which undergo the most often urological surgery group 1 penile surgery, group 2 inguinal surgery. group 3 renal surgery required nephrostomy tube leave or drainage. each group will be divided into two subgroups (20 patients each) with and without visual tutoring prior to the surgery. visual tutoring will include the photograph pictures reflecting different stage of the convalescent period following surgery. the parents will be asked to answer on questionnaire regarding the level of anxiety before surgery, immediately after surgery, week and 3-6 months after surgery. the number of parents calls to the hospital staff, emergency or outpatient clinic visit will be recorded and compared between two groups. the statistical analysis will performed utilizing graph pad prism version 5.00 for windows, (graph pad software, san diego, california, chi square and fisher test), considering p value of \<0.05 as significant).

Eligibility criteria:
inclusion criteria: * children with indications for penile, inguinal or kidney surgery exclusion criteria: * prior urological procedure (recurrent cases)

Keywords: children penile inguinal kidney parents anxiety
a study of rg1662 in adults and adolescents with down syndrome (clematis)

Conditions: Down Syndrome

Summary: this multi-center, randomized, double-blind, 3-arm, parallel-group, placebo-controlled study will evaluate the efficacy and safety of rg1662 in adults and adolescents with down syndrome. subjects will be randomized to receive rg1662 either at low or high dose or placebo orally twice daily for 26 weeks.


Eligibility criteria:
inclusion criteria: * individuals aged 12-30 years of age inclusive * clinical diagnosis of down syndrome (trisomy 21) confirmed by chromosomal analysis (karyotyping) * males, or non-pregnant, non-lactating females. for females of childbearing potential, strict contraceptive prevention is required. * body-mass index (bmi) 18-42 and 15-30 kg/m2 inclusive for adults and adolescents respectively * ability to complete the clinical evaluation of language fundamentals (celf)-preschool 2 word classes task * subjects must have a parent, or other reliable caregiver who agrees to accompany the subject to all clinic visits, provide information about the subject as required by the protocol, and ensure compliance with the medication schedule * study participants must have sufficient language, vision and hearing to participate in study evaluations, as judged clinically by investigator exclusion criteria: * subjects with a current dsm 5 diagnosis of any primary psychiatric diagnosis (including asd or mdd) * subjects with a history of infantile spasms, of west syndrome, lennox-gastaut syndrome, early infantile epileptic encephalopathy or any treatment-refractory epilepsy associated with cognitive or developmental regression, of severe head trauma or cns infections (e.g. meningitis) * subjects with a known or suspected clinical seizure event of any type within 24 months prior to screening * clinically relevant ecg abnormalities at screening or baseline; qtcf above 450 ms; personal or family history (first degree relatives) of congenital long qt syndrome * inadequate renal or hepatic function
effect of molecular hydrogen inhalation on metabolic response during low-intensity exercise on a bicycle ergometer

Conditions: Healthy; Respiratory Quotient Measurement

Summary: this trial evaluates the effect of molecular hydrogen inhalation on metabolic response, heart rate, and rating of perceived exertion in healthy females during 30 minutes of exercise on a bicycle ergometer.

the objective of this randomized, double-blind, placebo-controlled crossover trial is to assess the effect of molecular hydrogen inhalation on metabolic response during 20 min of rest and during exercise on a bicycle ergometer with a workload of 0.5 w/kg for 10 min, 0.75 w/kg for 10 min, and 1 w/kg for 10 min. the trial recruits healthy females aged 20-35 years and the planned sample size is 20. the trial consists of two experimental sessions, one using molecular hydrogen inhalation and the other using placebo inhalation. the washout period between sessions is one week. randomization of the order of the sessions is performed using a computer random generator. molecular hydrogen is produced using a hydrogen generator via electrolysis of water and administered through a mouthpiece. ambient air is used for placebo inhalation. molecular hydrogen is colorless, odorless, and tasteless, making it indistinguishable from placebo by the human senses. during the session, the following variables are measured: ventilation, oxygen uptake, respiratory exchange ratio, heart rate, rating of perceived exertion, and oxygen saturation. energy expenditure, fat oxidation rate and carbohydrates oxidation rate are calculated from oxygen uptake and respiratory exchange ratio. statistical analysis is performed at the 0.05 significance level and data are evaluated using analysis of variance for repeated measures with fisher's post hoc tests.

Eligibility criteria:
inclusion criteria: * free of major diseases. * signed informed consent. exclusion criteria: * acute conditions contraindicating laboratory testing of exercise. * cardiorespiratory disease. * pharmacotherapy affecting metabolism. * musculoskeletal problems.
follow-up of early breast cancer by dynamic evaluation of cea and ca 15.3 followed by 18fdg-pet

Conditions: Breast Cancer

Summary: the main purpose of follow-up in asymptomatic breast cancer patients during and after adjuvant treatment is to detect breast cancer recurrence and metastatic disease.the aim of this trial is to verify if, in asymptomatic patients, the serial measurement of serum cea and ca 15.3, with diagnostic imaging procedures (18fdg-pet) performed only in case of a critical increase of serum cea and ca 15.3 level, can anticipate the diagnosis of breast cancer local and distant recurrence compared to the usual follow-up practice.


Eligibility criteria:
inclusion criteria: * male or female ≥18 years. * histologically confirmed stage i-iii epithelial breast cancer. * adequate surgery of breast and axilla: 1. patients must have undergone either a total mastectomy or breast conserving surgery 2. surgical margins of the resected specimen must be histologically free of invasive tumor. * cohort 1: if chemotherapy and/or radiotherapy are indicated the patients must be randomized between 1 month and 2 months from the end of chemotherapy and/or radiotherapy; if only hormonal adjuvant therapy is indicated the patients must be randomized within 3 months from the completion of surgery * cohort 2: patients must be randomized in the trial after 5 years of follow-up without relapse (but within year 6) * signed informed consent obtained prior to any study-specific procedures. exclusion criteria: * histologically confirmed stage 0 epithelial breast cancer (carcinoma in situ). * special histologies with a high or low risk of relapse (i.e. sarcoma and tubular carcinoma) * t1a and t1b tumors with all the following characteristics: g1-2 and n0 and re \> 10%, rpg \> 10% and her2 negative and ki67≤14% * evidence of distant metastases * patients participating to other clinical trials requiring follow-up not equal to standard * previous history of cancer within 5 years from randomization (except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, stage i uterine cancer, or other non-breast malignancies with an outcome similar to those mentioned above)

Keywords: breast cancer follow-up tumor markers
multidimensional rehabilitation intervention in colorectal cancer survivors - a pilot study

Conditions: Rehabilitation; Colorectal Cancer Survivor; Quality of Life; Pilot Study

Summary: a metaverse-based multidimensional rehabilitation program will be implemented for colorectal cancer survivors who have undergone curative surgery and adjuvant therapy. the intervention is based on the behavior change wheel and includes dietary intervention, exercise intervention, psychological support, and behavior management. through various methods such as training, education, and motivation, the program aims to enhance the patients' functional ability, opportunities, and motivation, thereby promoting healthy behavior. outcome measures include quality of life, fear of recurrence, and adoption of a healthy lifestyle. the intervention period is 4 weeks, with evaluations conducted at baseline and week 4 of the intervention.


Eligibility criteria:
inclusion criteria: * patients undergoing adjuvant therapy after curative surgery for colorectal cancer.; * age 18 years old and under 65 years old, estimated survival period ≥ 6 months; * pg-sga (patient-generated subjective global assessment) score less than 4. * be able to walk without assistance; * conscious and intellectually normal; * voluntarily participate in the research of this topic and provide the consent form for medical record review; * mobile phones can be used. exclusion criteria: * patients with multiple cancers. * tumors not completely resected. * patients with severe psychological disorders, severe visual or hearing impairments, or other conditions that hinder intervention. * patients with severe complications such as short bowel syndrome, crohn's disease, ulcerative colitis, diverticulitis, previous stroke, congestive heart failure or edema, liver or kidney failure, or other conditions that affect patient compliance. * in addition to colorectal cancer or any other diseases deemed unsuitable for participation by the researchers, patients with severe heart, liver, lung, or kidney diseases. * patients with special dietary requirements.

Keywords: colorectal cancer survivor rehabilitation quality of life fear of cancer recurrence lifestyle home-based
ultra study for pacemaker patients

Conditions: Bradycardia

Summary: the ultra study will assess the difference in average ventricular voltage output for pacemaker patients randomized to automatic capture feature on versus patients randomized to automatic capture feature off.


Eligibility criteria:
inclusion criteria: * patients who meet current insignia® ultra pacemaker indications * patients who will be programmed to a pacing mode of ddd, dddr, vvi, vvir, or vdd at the time of implant * patients who sign and date a patient informed consent form at or prior to the implant visit * patients who remain in the clinical care of the enrolling physician in approved centers exclusion criteria: * patients who will receive a single chamber device with an atrial lead only * patients who have chronic leads with a ventricular threshold of more than 4.0 v * patients whose life expectancy is less than 12 months * patients who are expected to receive a heart transplant during the duration of the study * patients who have or who are likely to receive a tricuspid valve prosthesis * patients who are currently enrolled in another investigational study that would directly impact the treatment or outcome of the ultra study. * patients who are younger than 18 years of age * patients who are pregnant * patients who are mentally incompetent and cannot sign a patient informed consent form or comply with the study
prevalence and severity of molar incisor hypomineralization among a group of children with type i diabetes milletus.

Conditions: Molar Incisor Hypomineralization

Summary: * determine the prevalence of molar incisor hypomineralization among a group of children with type i diabetes millutes, its severity and treatment need via clinical examination of children with type i diabetes millutes . * teeth will be cleaned gently using gauze and wet with saliva during examination. a disposable diagnostic set (mirror, probe) will be used for each patient where mirrors will be used for proper visualization especially for maxillary teeth. * blunt explorers will be used to aid in tactile sensation if needed, as during the differentiation between rough and smooth enamel edges and/or during the inspection of the caries extent if it exists. no diagnostic radiographs will be taken. * the severity and treatment needs of each case with mih will be recorded in patient's chart. * the results of the study will be regularly monitored by the supervisors who will have full access to these results.

* this cross-sectional study will be carried out by recruiting a sample of participants previously diagnosed with type i diabetes millutes. * details regarding participant diagnosis and treatment of type i diabetes millutes will be obtained from medical records. this includes date and the age of the child on diagnosis type i diabetes millutes, and a recent hba1c level analysis within three months of the dental examination. * a disposable diagnostic set (mirror, probe) were used for each child to examine the four first permanent molars , the four maxillary ,the four mandibular incisors and second primary molars to detect the presence of molar incisor hypomineralization and its severity and scores will be recorded in the chart then it will be correlated with treatment need. * the teeth affected with molar incisor hypomineralization will be treated according to the recommendations of european academy of pediatric dentistry and the intervention will be recorded in patient's chart.

Eligibility criteria:
inclusion criteria: * patient aged 8 to 14 years and diagnosed with types i diabetes milletus. * eruption of all 4 first permanent molars. * acceptance to participate. exclusion criteria: * presence of orthodontic appliance. * patient with any other type of enamel defect. * patients with any other systemic conditions rather than types i diabetes milletus that may affect tooth development.

Keywords: molar incisor hypomineralization (mih) type i diabetes milletus(tidm)
characteristics of prader-willi syndrome and early-onset morbid obesity

Conditions: Prader-Willi Syndrome; Obesity

Summary: prader-willi syndrome (pws) is a rare genetic disorder that affects about 1 in 14,000 people in the united states. as the most commonly identified genetic cause of obesity, pws is often confused with early-onset morbid obesity (emo). individuals with emo show some signs of pws, but clinically do not have pws. the purpose of this study is to evaluate the clinical features and genetic basis of pws and emo, and to determine how these conditions affect a person throughout a lifetime.

pws is a complex neurobehavioral syndrome. clinical features include obesity, increased appetite, low muscle tone, cognitive impairment, distinct behavioral features, hypogonadism, and neonatal failure-to-thrive. it is the most commonly recognized genetic cause of obesity; however, many obese children do not in fact have pws. these individuals are therefore diagnosed with emo, a condition that shares features with pws. the development of new advances and strategies for treating pws and emo requires a thorough understanding of the conditions at both the clinical and molecular levels. one goal of this study is to collect long-term data on individuals with pws and emo in order to gain a better understanding of the natural progression of the conditions, from the neonatal period well into adulthood. specific to pws, this study will establish a genotype-phenotype correlation among the different sub-types and will evaluate the effects of growth hormone treatment on disease progression. lastly, the study will compare pws with emo in terms of clinical features and genetic basis. participation in this natural history study will entail an initial evaluation, followed by yearly study visits until the age of 3 and then every 2 years thereafter. each study visit will last between 3 and 4 hours, and will include a physical exam (including a dexa scan to determine body composition), psychological testing, an interview with the study physician, and an evaluation of the participant's diet history. in addition, blood tests will be completed for genetic testing and photos will be taken to evaluate disease progression. cognitive and behavioral assessments will also be conducted and will last between 10 and 30 minutes.

Eligibility criteria:
inclusion criteria: * individuals enrolling in the prader-willi syndrome group will have a confirmed diagnosis of prader-willi syndrome, as confirmed by molecular and cytogenetic testing * individuals enrolling in the early-onset morbid obesity group will have a documented medical history of their weight exceeding 150% of the ideal body weight or a body mass index greater than 97% before the age of 4 years; they will also be under the age of 30 years. exclusion criteria: * known genetic, chromosomal, or hormonal cause of cognitive impairment other than prader-willi syndrome

Keywords: early-onset morbid obesity
clinical trial of factor xiii (fxiii) concentrate

Conditions: Hemophilia; Factor XIII Deficiency

Summary: congenital deficiency of factor xiii is a rare but potentially life threatening disorder. it is inherited in an autosomal recessive fashion. infusion of factor xiii has proved to be useful for prevention and treatment of bleeding episodes, especially of spontaneous intracranial bleedings. in this study, fibrogammin p will be given to patients with congenital factor xiii deficiency and congenital/acquired fxiii deficiency to prevent bleeding and to treat established bleeding episodes. for factor xiii prophylaxis to prevent hemorrhages, the dosage will depend on the weight of the subject. the frequency of factor xiii administration will be determined by the factor's circulating half-life. during the first month only, a factor xiii pharmacokinetic study will be determined over a 4-week period. safety data will include accrual of information on viral safety, liver function, complete blood counts and adverse events. historical data concerning spontaneous bleeds will be collected whenever possible two years prior to treatment with fibrogammin p.


Eligibility criteria:
inclusion criteria: * patients may be of either sex or age. children and newborn infants are specifically included in this study. * patient must have documented congenital factor xiii deficiency * patient or legal guardian must sign informed consent * patients who have negative serology for hepatitis b should receive hepatitis b vaccination. exclusion criteria: * patient has acquired factor xiii deficiency

Keywords: factor xiii deficiency rare bleeding disorder hemophilia fibrogammin p
ultrafine particles and fetal contamination

Conditions: Lung; Premature; Pollution; Exposure

Summary: the objective of this study is to evaluate the transplacental passage of fine and ultrafine particles (nanoparticles) inhaled by the mother.

epidemiological studies have demonstrated the harmful effects of particulate air pollution on the progress of pregnancy and postnatal health. experimental studies have suggested the transplacental passage of asbestos fibers, but despite the strong growth in the use and production of fine and ultrafine particles, no study has examined the permeability of the placenta to these compounds or the exposures fetuses that may result. the objective of this study is to evaluate the transplacental passage of fine and ultrafine particles (nanoparticles) inhaled by the mother.

Eligibility criteria:
inclusion criteria: - all women volunteers for whom a medical termination of pregnancy is proposed for a fetus older than 22 weeks (weight over 500g). exclusion criteria: * refusal of participation of the patient. * fetus with malformation syndrome affecting pulmonary perfusion.

Keywords: atmospheric particles
utility of contrast-enhanced sonography and shear wave elastography

Conditions: Thyroid Nodule

Summary: our overall hypothesis is that contrast-enhanced ultrasound (ceus) and shear wave elastography (swe) will allow for high diagnostic accuracy of benign and malignant thyroid nodules, which will correlate with and complement the acr ti-rads classification system, allowing for more accurate diagnosis of benign and malignant thyroid nodules.

thyroid nodules are an exceedingly common clinical entity, however, only a small percentage of nodules are malignant. conventional ultrasound is the current standard for the initial evaluation of thyroid nodules, yet due to several overlapping characteristics between benign and malignant nodules its utility in diagnosis has been limited, leading to a high rate of negative biopsies. to overcome these challenges the american college of radiology has proposed a thyroid imaging reporting and data system (ti-rads) in an effort to decrease unnecessary biopsies \[5\]. while these efforts have shown encouraging results, further work is still needed. contrast-enhanced ultrasound (ceus) and shear wave elastography (swe) are two emerging non-invasive imaging techniques which have shown promising results in the evaluation of thyroid nodules. however, data is limited and how these imaging modalities could potentially compliment acr ti-rads is unknown.

Eligibility criteria:
inclusion criteria: * - patients over the age of 18 with one or more thyroid nodules diagnosed on conventional ultrasound within the last 6 months. * patients referred for standard of care thyroid nodule biopsy, ordered at the discretion of the treating physician and/or radiologists. * patients must demonstrate ability to understand and express willingness to sign a written informed consent to undergo swe and ceus imaging prior to their thyroid nodule biopsy. exclusion criteria: * patients who are pregnant, nursing, or less than 18 years of age * thyroid nodules ≤1 cm